A Phase 1, Double-Masked, Placebo-Controlled, Dose Escalating Study of the Safety, Tolerability, and Pharmacokinetics of EBI-005 Topically Administered to Eyes of Healthy Adult Subjects
Overview
- Phase
- Phase 1
- Intervention
- EBI-005-1
- Conditions
- Dry Eye
- Sponsor
- Eleven Biotherapeutics
- Enrollment
- 16
- Locations
- 1
- Primary Endpoint
- Changes from baseline in ocular safety measurements.
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
This is a First-In-Human (FIH) study to assess the safety and tolerability of ocular administration of EBI-005 in healthy volunteers. Additionally, the PK and immunogenicity of EBI-005 will be assessed.
Detailed Description
The planned dose levels are 5 mg/mL EBI-005 (Group 1) and 20 mg/mL EBI-005 (Group 2). A total of 8 subjects will be dosed in each group with subjects randomized in a ratio of 6:2, EBI-005:placebo. Treatment administration in Group 2 will proceed following a review of safety data from Group 1. In both groups, subjects randomized to active treatment will receive EBI-005 in the right eye and placebo in the left eye. Subjects randomized to placebo will receive placebo in each eye.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy adult males and/or females between the ages of 18 and 65 years
- •Medically healthy
- •Best correction vision of greater than or equal to 20/40 in each eye
- •Non-tobacco/nicotine-containing product users for a minimum of 6 months prior to dosing
- •Tolerate topical administration to eye
- •Signed and dated, Institutional Review Board (IRB) approved informed consent form (ICF) prior to any protocol-specific screening procedures
Exclusion Criteria
- •History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic (including sensitive skin on the face), neurological, or psychiatric disease, or any other clinically significant disease not deemed acceptable by the PI
- •History of any primary malignancy, with the exception of basal cell or squamous cell carcinomas of the skin or cervical carcinoma in situ or other malignancies curatively treated and with no evidence of disease for at least 5 years
- •Occurrence of active seasonal allergies including ocular allergies (e.g.; annual hay fever)
- •Abnormalities following ophthalmological examination: abnormality of the cornea, evidence of ocular inflammation (dry eyes, blepharitis, allergic conjunctivitis, iritis, and uveitis), glaucoma, and optic neuropathy
- •Subjects with a history of laser refractive surgery (laser assisted stromal in-situ keratomileusis \[LASIK\], photorefractive keratectomy \[PRK\]), radial keratotomy (RK), corneal transplantation, dry eyes, or radiotherapy to the eyes
- •Use of contact lenses currently or within the past one year
- •Positive urine drug/alcohol or cotinine testing
Arms & Interventions
EBI-005-1 5mg/mL
Healthy subjects will be randomized to EBI-005 5mg/mL vs. EBI-005-1 Placebo 3x/day
Intervention: EBI-005-1
EBI-005-1 5mg/mL
Healthy subjects will be randomized to EBI-005 5mg/mL vs. EBI-005-1 Placebo 3x/day
Intervention: EBI-005-1 Placebo
EBI-005-1 20 mg/mL
Healthy subjects will be randomized to EBI-005 20 mg/mL vs. EBI-005-1 Placebo 3x/day
Intervention: EBI-005-1
EBI-005-1 20 mg/mL
Healthy subjects will be randomized to EBI-005 20 mg/mL vs. EBI-005-1 Placebo 3x/day
Intervention: EBI-005-1 Placebo
Outcomes
Primary Outcomes
Changes from baseline in ocular safety measurements.
Time Frame: 1 week
Determined by best corrected visual acuity, slit lamp examination, measurement of intraocularpressure (IOP)
Secondary Outcomes
- ELISA based assay to determine Pharmacokinetics for the evaluation of systemic exposure of EBI-005 in healthy volunteers.(1 week)
- ELISA based assay to determine Immunogenicity for the evaluation of systemic exposure of EBI-005 in healthy volunteers.(1 week)